Biogen reports mixed Phase II results for LINGO antibody
Biogen Idec Inc. (NASDAQ:BIIB) said BIIB033 did not meet its primary or secondary endpoints in the Phase II RENEW trial to treat acute optic neuritis (AON) but termed the results "encouraging" by providing the first clinical evidence of the compound's effect on biological repair in the central nervous system (CNS) by facilitating remyelination following an acute inflammatory injury.
In the company's announcement, CMO Alfred Sandrock said data from the ongoing Phase II SYNERGY trial of BIIB033 to treat multiple sclerosis should provide a more complete understanding of the compound's potential. Those data are expected in 2016. Both Phase II trials were designed to evaluate the biological activity and clinical potential of the antibody against leucine-rich repeat neuronal protein 1 ( LINGO-1) in demyelinating diseases such as AON, or inflammation of the optic nerve. According to clinicaltrials.gov, the primary endpoint in the MS study is improvement of neuro-physical and/or cognitive function and/or disability. ...